Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State or other ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Ed White - H.C. Wainwright Divya Rao - TD Cowen This concludes todayÂ's presentation. We will now turn the floor back to the operator for Q&A. Operator? [Operator Instructions] Thank you. And your first question comes from Ed White with H.C. Wainwright. Please proceed with your question Ed White No, free drug. Alan Auerbach Alan Auerbach Maximo Nougues So Ed, in terms of patient assistance programs, are you talkin ...

业绩总结 - 2023年第一季度NERLYNX净收入约为4700万美元[5] - 2023年第一季度销售的NERLYNX药瓶数量为2849瓶[7] - 2023年第一季度，Puma的药物销售表现显示出稳定的市场需求[5] 用户数据 - 约64%的患者在2023年第一季度以减少剂量开始治疗[9] 市场扩张 - 2023年第一季度在哥伦比亚获得了mBC的批准[10] - 2023年第一季度，Puma的药物销售网络包括多个学术医院和社区医院[3] - 2023年第一季度，Puma的药物销售渠道包括多个专业药房和分销商[3] - 2023年第一季度，Puma在全球范围内的药物监管批准情况持续推进[10] 未来展望 - Puma的前瞻性声明强调了COVID-19疫情对业务的潜在影响[2] - 2022年12月31日的年度报告中披露的风险因素可能影响实际结果[2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State or othe ...

Patients Sites of Care Academic Hospitals Community Hospitals Physician Practices Others (VA, DOD) Hub Services Specialty Pharmacy Network (SP) Specialty Distributor Network (SD) Acaria Health Accredo CVS ONCO 360 Optum / Diplomat Biologics Cardinal Health McKesson ASD/Oncology Supply DMS Pharmaceutical Group Inc. 6.1 20.1 36.0 50.8 52.6 61.1 45.6 53.8 53.5 58.7 48.6 48.8 49.3 50.0 45.8 48.9 43.4 51.0 40.7 51.3 54.3 53.7 Bottles Sold (SP + SD) by Quarter ~64% of patients in Q4'22 started at a reduced dose* ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Based on recent precedence and interactions with the FDA which suggested that regulatory approval in these indications would require a randomized trial, the company will not be further pursuing the development of neratinib in these indications. In September, Puma was pleased to announce that we in-licensed the anticancer drug alisertib from Takeda. In clinical trials to date, alisertib has shown single agent act ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State o ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Operator Good afternoon. My name is Paul and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Alex, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference ca ...

Puma Biotechnology Earnings Call Commercial Update May 5, 2022 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statem ...